The Clinical Efficacy and Safety of Ertapenem for the ... | 合法藥品大搜索

由 MF Lartigue 著作 · 2007 · 被引用 122 次 — An ertapenem-resistant Escherichia coli isolate was recovered from peritoneal fluid in a patient who had been treated with imipenem/cilastatin for 10 days. Read More

由 CA DeRyke 著作 · 2007 · 被引用 62 次 — Therefore, the objective of this study was to compare the efficacies of meropenem and ertapenem against ESBL-producing E. coli and K. pneumoniae isolates, ... Read More

由 RM Mody 著作 · 2007 · 被引用 39 次 — Ertapenem susceptibility of ESBL-producing E. coli and K. pneumoniae clinical isolates were evaluated and compared to imipenem to determine ... Read More

由 D Maglio 著作 · 2005 · 被引用 23 次 — Extended-spectrum beta-lactamase (ESBL)-positive and ESBL-negative clinical strains of Escherichia coli and Klebsiella pneumoniae were studied. MICs ranged​ ... Read More

由 B Gutiérrez-Gutiérrez 著作 · 2016 · 被引用 41 次 — Patients given monotherapy with ertapenem or other carbapenems were ... Ertapenem MICs are usually higher for these isolates than for E. coli, again ... Read More

由 D Girlich 著作 · 2009 · 被引用 65 次 — In E. coli as well as in K. pneumoniae isolates, mean frequencies of selection of ertapenem-reduced susceptibility were not related to the blaCTX-M content (P > ... Read More

由 A Karaaslan 著作 · 被引用 11 次 — Escherichia coli (E. coli) ( ; 87%) was the most common bacterial cause of the ... Ertapenem is a newer carbapenem with the advantage of once-daily dosing and​ ... Read More

由 DC Lye 著作 · 2008 · 被引用 35 次 — Ertapenem is promising in culture-guided step-down therapy of ESBL-positive ... Klebsiella pneumoniae comprised 53% and Escherichia coli 26%. Urinary ... Read More

由 B Gutiérrez-Gutiérrez 著作 · 2016 · 被引用 41 次 — UTI as source and E. coli were more frequent among patients treated with ertapenem, while ICU admission, nosocomial infections, cancer and ... Read More

大腸桿菌中，ertapenem 對PBPs 1a, 1b, 2, 3, 4, 和5 有很強的親和力，尤其是. PBPs 2 和3。 ... Ertapenem 可以100% (3/3)成功地治療感染E. coli 菌血症的病人。 Read More